Olink Proteomics

Developing technology for human protein biomarker research

Company details

Year Aquired

2019

Location

Uppsala, Sweden

Revenue

NA

Sector

Life Science

Employees

Investment Themes

Changing Demographics

Contact

If you want to know more about Olink Proteomics please contact Tommi Unkuri at: tommi.unkuri@summaequity.com

Olink has a unique technology for protein analysis in human protein biomarker research for a more efficient and precise analysis of large numbers of proteins. This technology drives precision medicine by improving the understanding of the interaction of proteins and human disease which is key to improve treatment and patient outcomes across many disease areas.

 

Challenge

The field of proteomics has been determined to be one of the most important research areas to fully understand and characterize disease. However, the scientific community has lacked strong technologies and solutions to advance this research over the past decades.

How do we solve it?

Olink’s proprietary Proximity Extension Assay (PEA) technology enables researchers to analyse large numbers of proteins with high-throughput analysis, exceptional data quality, and minimal sample consumption. This enables research that previously could not be done.

 

How do we improve?

Over the next few years, Olink will scale up operations across markets and applications to drive significant benefits for customers, patients and the research community worldwide.

 

Value creation

Olink has experienced rapid growth in recent years and will continue to see high growth for years to come. The company will focus on building an organization that can support the growing global demand from an continuously expanding customer base, as well as continue development of its technology to address additional applications within proteomics.

Year Aquired

2019

Revenue

NA

Employees

Investment Themes

Changing Demographics

Sector

Life Science

Location

Uppsala, Sweden

Contact

If you want to know more about Olink Proteomics please contact Tommi Unkuri at: tommi.unkuri@summaequity.com

Website

Video

Learn more about EcoOnline

Olink Proteomics AB announce acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays

Dear Friends, UPPSALA, Sweden, May 12, 2020 – Olink today announced the acquisition of Agrisera AB, a Swedish company specializing in polyclonal and monoclonal antibody production. Agrisera offers an extensive collection of primary and secondary antibodies for a broad range of applications, available in various quantities. The acquisition is an important milestone for Olink in its…

Read the story

Summa Equity acquires Olink Proteomics

Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity is excited to support this development, and to…

Read the story

Olink Proteomics AB announce acquisition of Agrisera AB to accelerate production of dedicated antibodies for development of new immunoassays

Dear Friends, UPPSALA, Sweden, May 12, 2020 – Olink today announced the acquisition of Agrisera AB, a Swedish company specializing in polyclonal and monoclonal antibody production. Agrisera offers an extensive collection of primary and secondary antibodies for a broad range of applications, available in various quantities. The acquisition is an important milestone for Olink in its...
Learn more

Summa Equity acquires Olink Proteomics

Summa Equity acquires Olink Proteomics, a Swedish life science company that has developed a unique technology for human biomarker discovery, targeting the global biopharma and academic research and discovery markets. Olink’s purpose is to enable precision medicine through proteomics, thereby contributing to advancing healthcare worldwide. Summa Equity is excited to support this development, and to...
Learn more